CYP2D6 and Tamoxifen: Awaiting the Denouement Reply

被引：0
作者：
Rae, James M. [1 ]
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 34期
关键词：
PHARMACOGENETICS; METABOLITE;
D O I：
10.1200/JCO.2011.39.0971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4590 / 4591
页数：3
相关论文
共 50 条
[1]   Tamoxifen and CYP2D6: A Contradiction of Data [J].
Hertz, Daniel L. ;
McLeod, Howard L. ;
Irvin, Dwilliam J., Jr. .
ONCOLOGIST, 2012, 17 (05) :620-630
[2]   CYP2D6 Polymorphisms and the impact on tamoxifen therapy [J].
Beverage, Jacob N. ;
Sissung, Tristan M. ;
Sion, Amy M. ;
Danesi, Romano ;
Figg, William D. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (09) :2224-2231
[3]   Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment [J].
Charoenchokthavee, Wanaporn ;
Panomvana, Duangchit ;
Sriuranpong, Virote ;
Areepium, Nutthada .
BREAST CANCER-TARGETS AND THERAPY, 2016, 8 :149-155
[4]   Should CYP2D6 be genotyped when treating with tamoxifen? [J].
Del Re, Marzia ;
Rofi, Eleonora ;
Citi, Valentina ;
Fidilio, Leonardo ;
Danesi, Romano .
PHARMACOGENOMICS, 2016, 17 (18) :1967-1969
[5]   Should CYP2D6 be genotyped when treating with tamoxifen? [J].
Del Re, Marzia ;
Rofi, Eleonora ;
Citi, Valentina ;
Fidilio, Leonardo ;
Danesi, Romano .
PHARMACOGENOMICS, 2017, 18 (08) :755-756
[6]   CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance [J].
Higgins, Michaela J. ;
Stearns, Vered .
CURRENT ONCOLOGY REPORTS, 2010, 12 (01) :7-15
[7]   CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance [J].
Michaela J. Higgins ;
Vered Stearns .
Current Oncology Reports, 2010, 12 :7-15
[8]   CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug? [J].
von Ahsen, Nicolas ;
Binder, Claudia ;
Brockmoeller, Juergen ;
Oellerich, Michael .
LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2009, 33 (05) :293-302
[9]   Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? [J].
Del Re, M. ;
Citi, V. ;
Crucitta, S. ;
Rofi, E. ;
Belcari, F. ;
van Schaik, R. H. ;
Danesi, R. .
PHARMACOLOGICAL RESEARCH, 2016, 107 :398-406
[10]   Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we? [J].
Huber-Wechselberger, Ariana E. ;
Niedetzky, Paul ;
Aigner, Irene ;
Haschke-Becher, Elisabeth .
WIENER MEDIZINISCHE WOCHENSCHRIFT, 2012, 162 (11-12) :252-261
12345